Impact of adjuvant therapeutic surgery on the health-related quality of life of pulmonary tuberculosis patients

Pau Benito, Sergo Vashakidze, Shota Gogishvili, Keti Nikolaishvili, Albert Despuig, Nestan Tukvadze, Natalia Shubladze, Zaza Avaliani, Cristina Vilaplana, Pau Benito, Sergo Vashakidze, Shota Gogishvili, Keti Nikolaishvili, Albert Despuig, Nestan Tukvadze, Natalia Shubladze, Zaza Avaliani, Cristina Vilaplana

Abstract

This study aimed to determine the health-related quality of life (HRQoL) of patients with pulmonary tuberculosis (TB) and to assess its change after a therapeutic surgical procedure. In this scenario, the purpose was to elucidate and quantify the effect of various demographic, epidemiological, clinical, surgical and psychosocial details on this variable. A prospective cohort of 40 patients undergoing therapeutic surgery for pulmonary TB (Study of Human Tuberculosis Lesions (SH-TBL) cohort) was recruited in Tbilisi, Georgia, between 2016 and 2018. HRQoL was assessed by administering the St George's Respiratory Questionnaire (SGRQ) and a novel psychosocial questionnaire, the BCN-Q, both at baseline and at 6 months post-surgery. A statistically and clinically significant improvement in the SGRQ total score was observed at follow-up, although it did not reach the values found for the healthy population. The differences between time points were statistically significant for the following groups: women, age <40 years, body mass index ≥20 kg·m-2, nonsmokers, drug-susceptible and drug-resistant participants, both new and relapsed patients, early culture negativisation, cases with a single lesion, either lesions <35 mm or ≥35 mm, and lesion, lobe and lung resections. The analysis of BCN-Q together with the SGRQ showed that several of its items, such as marital status, living conditions, nutrition, employment, external support, certain attitudes towards the healthcare system, emotional burden and sleep troubles, can impact HRQoL. These results highlight the benefit of adjuvant therapeutic surgery for pulmonary TB in selected patients in terms of HRQoL and suggest that a comprehensive approach including demographic, epidemiological, clinical and psychosocial variables may more accurately predict TB evolution and prognosis.

Conflict of interest statement

Conflict of interest: P. Benito has nothing to disclose. Conflict of interest: S. Vashakidze has nothing to disclose. Conflict of interest: S. Gogishvili has nothing to disclose. Conflict of interest: K. Nikolaishvili has nothing to disclose. Conflict of interest: A. Despuig reports grants from Spanish Government-FEDER Funds and the CIBER Enfermedades Respiratorias Network (CIBERES), and personal fees from Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, during the conduct of the study. Conflict of interest: N. Tukvadze has nothing to disclose. Conflict of interest: N. Shubladze has nothing to disclose. Conflict of interest: Z. Avaliani has nothing to disclose. Conflict of interest: C. Vilaplana reports personal fees from Spanish Government-FEDER Contratos Miguel Servet, and grants from Spanish Government-FEDER, CIBERES), grants from the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), during the conduct of the study.

Copyright ©ERS 2020.

Figures

FIGURE 1
FIGURE 1
St George's Respiratory Questionnaire (SGRQ) score change according to time point. Graphs show the participants’ score for each of the components of the questionnaire (a: symptoms, b: activity and c: impacts), as well as their overall total score (d) at both time-points.
FIGURE 2
FIGURE 2
St George's Respiratory Questionnaire (SGRQ) total score change according to clinical and demographic characteristics of participants and time point: a) sex, b) age, c) body mass index (BMI) and d) smoking status. Circular and square symbols correspond to data from the first visit and follow-up, respectively.
FIGURE 3
FIGURE 3
St George's Respiratory Questionnaire (SGRQ) total score change according to tuberculosis and surgery-related information of participants and time point: a) drug susceptibility, b) history of previous treatment, c) time to culture negativisation, d) number and e) size of lesions and f) type of resection. Circular and square symbols correspond to data from the first visit and follow-up, respectively. DS: drug-susceptible; MDR: multidrug resistant; XDR: extensively drug-resistant.
FIGURE 4
FIGURE 4
St George's Respiratory Questionnaire (SGRQ) total score change according to answers to the BCN-Q and time point. Graphs show the score differences depending on a) family or marital status, b) occupation, c) number of cohabitants, d) family financial support, e) need to take care of somebody, f) job loss due to tuberculosis, g) meat, fish and eggs intake, h) dairy products intake, i) use of traditional medicine, j) sleep troubles, k) emotional burden and l) multidrug resistant (MDR)/extensively drug-resistant (XDR) sequelae. Circular and square symbols correspond to data from the first visit and follow-up, respectively.

References

    1. The Regional Office for Europe of the World Health Organization. The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB. Copenhagen, WHO Regional Office for Europe, 2014.
    1. World Health Organization. Global tuberculosis report 2018. Geneva, World Health Organization, 2018.
    1. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2019.
    1. World Health Organization. Implementing the End TB Strategy: the essentials. Geneva, World Health Organization, 2015.
    1. Jones P. St George's Respiratory Questionnaire Manual. Saint George's, University of London, 2009.
    1. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85: Suppl. B, 25–31. doi:10.1016/S0954-6111(06)80166-6
    1. Jones PW, Quirk FH, Baveystock CM, et al. . A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327. doi:10.1164/ajrccm/145.6.1321
    1. Chang B, Wu AW, Hansel NN, et al. . Quality of life in tuberculosis: a review of the English language literature. Qual Life Res 2004; 13: 1633–1642. doi:10.1007/s11136-004-0374-1
    1. Brown J, Capocci S, Smith C, et al. . Health status and quality of life in tuberculosis. Int J Infect Dis 2015; 32: 68–75. doi:10.1016/j.ijid.2014.12.045
    1. Ferrer M, Villasante C, Alonso J, et al. . Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002; 19: 405–413. doi:10.1183/09031936.02.00213202
    1. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398–404. doi:10.1183/09031936.02.00063702
    1. Vashakidze SA, Kempker JA, Jakobia NA, et al. . Pulmonary function and respiratory health after successful treatment of drug-resistant tuberculosis. Int J Infect Dis 2019; 82: 66–72. doi:10.1016/j.ijid.2019.02.039
    1. Hertz D, Schneider B. Sex differences in tuberculosis. Semin Immunopathol 2019; 41: 225–237. doi:10.1007/s00281-018-0725-6
    1. Vashakidze S, Despuig A, Gogishvili S, et al. . Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for pulmonary tuberculosis in Georgia. Int J Infect Dis 2017; 56: 200–207. doi:10.1016/j.ijid.2016.12.009
    1. Byng-Maddick R, Noursadeghi M. Does tuberculosis threaten our ageing populations? BMC Infect Dis 2016; 16: 119. doi:10.1186/s12879-016-1451-0
    1. Chandrasekaran P, Saravanan N, Bethunaickan R, et al. . Malnutrition: modulator of immune responses in tuberculosis. Front Immunol 2017; 8: 1–8. doi:10.3389/fimmu.2017.01316
    1. Hoyt KJ, Sarkar S, White L, et al. . Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis. PLoS ONE 2019; 14: 1–11. doi:10.1371/journal.pone.0214011
    1. Bhargava A, Chatterjee M, Jain Y, et al. . Nutritional status of adult patients with pulmonary tuberculosis in rural Central India and its association with mortality. PLoS ONE 2013; 8: 1–11. doi:10.1371/journal.pone.0077979
    1. Leung CC, Yew WW, Chan CK, et al. . Smoking adversely affects treatment response, outcome and relapse in tuberculosis. Eur Respir J 2015; 45: 738–745. doi:10.1183/09031936.00114214
    1. Kempker RR, Vashakidze S, Solomonia N, et al. . Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 157–166. doi:10.1016/S1473-3099(11)70244-4
    1. Abdulelah J, Sulaiman SAS, Hassali MA, et al. . Development and psychometric properties of a tuberculosis-specific multidimensional health-related quality-of-life measure for patients with pulmonary tuberculosis. Value Health Reg Issues 2015; 6: 53–59. doi:10.1016/j.vhri.2015.03.006
    1. Sun Y, Yang Z, Wan C, et al. . Development and validation of the pulmonary tuberculosis scale of the system of quality of life instruments for chronic diseases (QLICD-PT). Health Qual Life Outcomes 2018; 16: 137–146. doi:10.1186/s12955-018-0960-5
    1. Boudioni M, McLaren S, Belling R, et al. . Listening to those on the frontline: service users’ experiences of London tuberculosis services. Patient Prefer Adherence 2011; 5: 267–277. doi:10.2147/PPA.S20361
    1. Hansel NN, Wu AW, Chang B, et al. . Quality of life in tuberculosis: patient and provider perspectives. Qual Life Res 2004; 13: 639–652. doi:10.1023/B:QURE.0000021317.12945.f0
    1. Odone A, Houben RMGJ, White RG, et al. . The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol 2014; 2: 754–764. doi:10.1016/S2213-8587(14)70164-0
    1. Koethe JR, Von Reyn CF. Protein-calorie malnutrition, macronutrient supplements, and tuberculosis. Int J Tuberc Lung Dis 2016; 20: 857–863. doi:10.5588/ijtld.15.0936
    1. Kant S, Gupta H, Ahluwalia S. Significance of nutrition in pulmonary tuberculosis. Crit Rev Food Sci Nutr 2015; 55: 955–963. doi:10.1080/10408398.2012.679500
    1. Frediani JK, Sanikidze E, Kipiani M, et al. . Macronutrient intake and body composition changes during anti- tuberculosis therapy in adults. Clin Nutr 2016; 35: 205–212. doi:10.1016/j.clnu.2015.02.007
    1. Rieder H. Epidemiologic basis of tuberculosis control. Paris, International Union Against Tuberculosis and Lung Disease, 1999.
    1. Zürcher K, Ballif M, Zwahlen M, et al. . Tuberculosis mortality and living conditions in Bern, Switzerland, 1856–1950. PLoS ONE 2016; 11: e0149195. doi:10.1371/journal.pone.0149195
    1. Martire LM, Helgeson VS. Close relationships and the management of chronic illness: associations and interventions. Am Psychol 2017; 72: 601–612. doi:10.1037/amp0000066
    1. World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. A67/11. Geneva, World Health Organization, 2014.
    1. Lönnroth K, Glaziou P, Weil D, et al. . Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med 2014; 11: e1001693. doi:10.1371/journal.pmed.1001693
    1. Tola HH, Shojaeizadeh D, Garmaroudi G, et al. . Psychological distress and its effect on tuberculosis treatment outcomes in Ethiopia. Glob Health Action 2015; 8: 29019. doi:10.3402/gha.v8.29019
    1. Akinci B, Aslan GK, Kiyan E. Sleep quality and quality of life in patients with moderate to very severe chronic obstructive pulmonary disease. Clin Respir J 2018; 12: 1739–1746. doi:10.1111/crj.12738
    1. Scharf SM, Maimon N, Simon-Truval T, et al. . Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 6: 1–12. doi:10.2147/COPD.S15666
    1. Vardar-Yagli N, Saglam M, Savci S, et al. . Impact of sleep quality on functional capacity, peripheral muscle strength and quality of life in patients with chronic obstructive pulmonary disease. Expert Rev Respir Med 2015; 9: 233–239. doi:10.1586/17476348.2015.1009041
    1. Chang CH, Chuang LP, Lin SW, et al. . Factors responsible for poor sleep quality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2016; 16: 118–125. doi:10.1186/s12890-016-0281-6
    1. Sagwa EL, Ruswa N, Mavhunga F, et al. . Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia. Patient Prefer Adherence 2016; 10: 2369–2377. doi:10.2147/PPA.S116860
    1. Sineke T, Evans D, Schnippel K, et al. . The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes 2019; 17: 94–108. doi:10.1186/s12955-019-1155-4

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere